Company overview
Bruker designs, manufactures, and services high-performance analytical instruments for pharmaceutical drug discovery, development, and manufacturing. The company provides mass spectrometers, NMR systems, FT-IR/FT-NIR, X-ray, and AFM platforms for small molecule and biopharmaceutical analysis. With FY2023 revenue of approximately $3.05 billion and global operations, Bruker delivers integrated workflows combining precision instrumentation with recurring services, consumables, and AI-driven software solutions.
Pharmaceutical & Biopharmaceutical Analysis Instruments is listed in the NovaPharmaNews Supplier Hub as a Lab Equipment & Instruments partner serving United States & Americas. Core focus areas include pharmaceutical instruments, nmr spectrometry, mass spectrometry, drug discovery, biopharmaceutical analysis.
Industry categories: Lab Equipment & Instruments. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Pharmaceutical & Biopharmaceutical Analysis Instruments include Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.bruker.com/en/applications/pharma.html
- Categories
- Lab Equipment & Instruments
- Markets served
- United States & Americas
- Keywords
- pharmaceutical instruments, nmr spectrometry, mass spectrometry, drug discovery, biopharmaceutical analysis
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What analytical instruments does Bruker offer for pharmaceutical applications?
- Bruker provides a comprehensive suite of instruments including mass spectrometers, NMR systems, FT-IR/FT-NIR, X-ray diffraction, and atomic force microscopy (AFM) platforms. These instruments support both small molecule and biopharmaceutical drug manufacturers across discovery, development, and manufacturing stages.
- What is Bruker's revenue model and geographic presence?
- Bruker generated approximately $3.05 billion in FY2023 revenue with near 20% non-GAAP operating margins. Revenue is driven by instrument sales (55-65% of revenue) supplemented by recurring services and consumables (30-40%). Geographic distribution includes Europe (35-40%), Americas (35-40%), and APAC (25-30%).
- Does Bruker offer specialized services for drug discovery and development?
- Yes. Bruker has partnered with NovAliX to enhance drug discovery through advanced biophysical and structural biology methods, including molecular dynamics characterization and drug candidate interaction analysis. The company also offers AI-driven active pharmaceutical ingredient (API) production solutions with real-time benchtop NMR control and label-free bioparticle characterization platforms.
- What recent strategic investments has Bruker made in the pharmaceutical sector?
- Bruker acquired PhenomeX, a specialty cellular analysis company, and made a minority investment in NovAliX, a French preclinical Contract Research Organisation. Additionally, Bruker announced $500 million in multi-year orders from two global healthcare companies for high-performance superconductors for MRI systems.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
- Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen
- BBSW AI Solution Event: Daily Roundup
- BBSW AI Solution Event: Biotech Innovation in US
Explore lab tools and QA/QC resources for R&D teams.
